심장 유전학 검사 시장 : 전략적 인사이트와 예측(2026-2031년)

The Cardiogenetic Testing Market is forecast to grow at a CAGR of 11.9%, reaching USD 13.06 billion in 2031 from USD 4.76 billion in 2026.

The global cardiogenetic testing market is experiencing rapid expansion, driven by the growing integration of genomics into cardiovascular medicine and the increasing recognition of inherited cardiac disorders. Cardiogenetic testing identifies pathogenic genetic variants associated with inherited cardiovascular diseases including cardiomyopathies, inherited arrhythmia syndromes, familial hypercholesterolemia, and connective tissue disorders affecting the cardiovascular system. The market encompasses laboratory-developed tests, targeted gene panels, whole exome sequencing, whole genome sequencing, bioinformatics platforms, interpretation software, and genetic counseling services that collectively support clinical decision-making. Demand is increasing because cardiovascular specialists are recognizing that phenotypic assessment alone frequently cannot distinguish hereditary disease from acquired cardiac disorders. Earlier molecular confirmation supports personalized monitoring strategies, guides therapeutic interventions, and enables family-based cascade testing. Regulatory agencies and professional medical societies continue emphasizing standardized laboratory quality, analytical validity, and evidence-based clinical reporting, reinforcing confidence in genomic diagnostics. Healthcare providers increasingly integrate multidisciplinary genetic counseling with cardiovascular care, allowing test results to translate into long-term disease management rather than isolated diagnostic findings. This evolution strengthens the strategic importance of cardiogenetic testing within precision medicine programs worldwide.

Market Drivers

Expanding Clinical Adoption of Precision Cardiology

• Precision cardiology integrates genomic information with conventional cardiovascular assessment to improve diagnosis and treatment selection. Healthcare providers are increasingly adopting genetic testing because inherited cardiovascular disorders often present with overlapping clinical features that complicate conventional diagnosis. Earlier molecular confirmation reduces diagnostic uncertainty while supporting personalized surveillance and therapeutic planning. Diagnostic laboratories are expanding specialized cardiovascular testing portfolios to address this growing clinical demand. The increasing incorporation of genomics into cardiovascular practice strengthens long-term adoption across tertiary hospitals and specialized cardiac centers.

Rising Demand for Family-Based Cascade Screening

• Inherited cardiovascular disorders frequently affect multiple generations within the same family. Healthcare providers recommend cascade genetic testing because identifying pathogenic variants among relatives enables preventive monitoring before symptoms develop. Clinical awareness is increasing as professional societies emphasize family-based risk assessment for inherited cardiac diseases. Diagnostic laboratories are developing streamlined testing workflows that facilitate screening of multiple family members. Earlier identification of genetically predisposed individuals reduces disease burden through proactive clinical management.

Continuous Advancements in Sequencing Technologies

• Sequencing technologies continue improving analytical sensitivity, throughput, and cost efficiency. Laboratories are increasingly implementing next-generation sequencing platforms because they simultaneously evaluate numerous cardiovascular genes with greater efficiency than sequential testing approaches. Improved bioinformatics pipelines enhance variant interpretation and reduce reporting variability across laboratories. Technology developers continue introducing automation and artificial intelligence-assisted analytical tools that improve laboratory productivity. These innovations strengthen confidence among clinicians and expand the accessibility of comprehensive cardiogenetic testing.

Increasing Integration of Genetic Counseling into Cardiovascular Care

• Effective interpretation of genetic findings requires specialized counseling before and after testing. Healthcare systems increasingly recognize that multidisciplinary care improves clinical utility and patient understanding of inherited cardiovascular risk. Hospitals are integrating genetic counselors within cardiovascular programs to support informed testing decisions and long-term family management. This coordinated care model enhances patient adherence while improving the clinical value of genetic information. The integration of counseling services strengthens adoption by reducing uncertainty surrounding complex genomic findings.

Market Restraints

• Limited reimbursement coverage across several healthcare systems continues restricting patient access to comprehensive cardiogenetic testing despite expanding clinical evidence. Interpretation of variants of uncertain significance remains challenging, creating clinical uncertainty that may delay treatment decisions and require additional genetic evaluation. Shortages of trained clinical geneticists and genetic counselors limit testing capacity and reduce the efficiency of precision cardiovascular care delivery. Additionally, data privacy concerns regarding genomic information can influence patient and provider acceptance.

Technology and Segment Insights

By Test Type

• Diagnostic testing represents the largest application segment because it confirms the molecular basis of inherited cardiovascular disorders in symptomatic individuals. Healthcare providers are increasingly requesting comprehensive genetic evaluation when conventional clinical findings cannot distinguish between phenotypically similar diseases. Predictive and presymptomatic testing enables risk assessment for asymptomatic individuals with a family history of inherited cardiac conditions. Carrier testing identifies individuals carrying genetic variants for autosomal recessive or X-linked disorders. Cascade testing facilitates family-based screening after a pathogenic variant is identified in a proband. Prenatal and preimplantation genetic testing supports reproductive decision-making for couples at risk of passing on inherited cardiovascular disorders.

By Technology

• Next-generation sequencing dominates the technology landscape because it enables simultaneous analysis of numerous cardiovascular genes with high analytical sensitivity. Laboratories are increasingly adopting NGS platforms as demand shifts toward comprehensive genomic evaluation. Whole exome sequencing and whole genome sequencing provide the broadest genomic coverage for complex or atypical presentations. Targeted gene panel testing offers a balanced approach between cost and comprehensiveness for specific disease categories. Sanger sequencing remains important for targeted variant confirmation and familial segregation analysis. PCR-based testing provides rapid analysis for specific mutations. Chromosomal microarray analysis detects copy number variations.

By Disorder Type

• Inherited cardiomyopathies, including hypertrophic cardiomyopathy, dilated cardiomyopathy, and arrhythmogenic cardiomyopathy, constitute a major clinical application because they frequently result from pathogenic variants affecting cardiac muscle structure and function. Inherited arrhythmia syndromes, such as long QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia, represent another significant segment. Familial aortopathies and connective tissue disorders, including Marfan syndrome and Loeys-Dietz syndrome, are important indications. Familial hypercholesterolemia is a major segment driving testing for early identification and management of extreme lipid risk. Other inherited cardiovascular disorders contribute to the diversity of the market.

By End User

• Hospitals and specialty cardiology clinics represent significant end-user segments, integrating genetic testing into cardiovascular care pathways. Diagnostic laboratories are the primary service providers, offering comprehensive testing panels and interpretation. Academic and research institutes contribute to test development and clinical validation.

Competitive and Strategic Outlook

• The competitive landscape features major diagnostic and sequencing companies. F. Hoffmann-La Roche Ltd. maintains a strong strategic position through its integrated diagnostics portfolio, sequencing technologies, and global molecular diagnostics infrastructure. Illumina, Inc. remains the global leader in next-generation sequencing technologies, providing foundational platforms for numerous cardiogenetic testing laboratories. Eurofins Scientific SE operates one of the world's largest laboratory networks, providing comprehensive genetic testing services. Quest Diagnostics Incorporated and Laboratory Corporation of America Holdings (Labcorp) are leading diagnostic information service providers with extensive molecular and hereditary disease testing portfolios. Invitae Corporation has established a strong reputation in hereditary genetic testing with broad multi-gene panels. Natera, Inc. applies advanced cell-free DNA analysis and molecular diagnostics expertise. GeneDx Holdings Corp. specializes in rare disease and whole exome/genome sequencing diagnostics.
• Strategic developments include increasing integration of artificial intelligence for variant interpretation, expansion of preventive genomic screening programs, and growth of personalized cardiovascular therapeutics. Companies are forming partnerships with healthcare providers, pharmaceutical companies, and research institutions to support biomarker discovery and precision medicine. Service expansions focus on comprehensive gene panels, advanced bioinformatics, and integrated genetic counseling. Companies that successfully combine advanced sequencing technologies, robust clinical interpretation, and scalable laboratory operations are expected to maintain competitive leadership.

Conclusion

• The cardiogenetic testing market is poised for substantial growth, driven by the expanding clinical adoption of precision cardiology, advancements in sequencing technologies, and the increasing recognition of inherited cardiac disorders. The evolution toward comprehensive genomic testing supporting early diagnosis, family-based screening, and personalized management is reshaping cardiovascular care. Companies that successfully deliver integrated, clinically validated, and accessible genetic testing solutions are expected to lead the market. Ongoing technological innovation, regulatory support, and expanding healthcare infrastructure across emerging economies will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Cardiogenetic Testing Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Overview of Cardiogenetic Testing
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2031)
• 3.7 Cardiovascular Genetic Disorders Overview
• 3.8 Disease Burden & Unmet Clinical Needs
• 3.9 Epidemiology & Prevalence Analysis
• 3.10 Diagnosed Patient Population Analysis
• 3.11 Genetic Testing Adoption Analysis
• 3.12 Clinical Utility of Cardiogenetic Testing
• 3.13 Patient Journey Analysis

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies
• 6.2 Product Innovation
• 6.3 Clinical Trial Analysis
• 6.4 Pipeline Analysis
• 6.5 AI Integration in Cardiogenetic Testing
• 6.6 Digital Health Integration

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Cardiogenetic Testing Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Testing Methodology
• 8.3 Analysis by Biomarker Type
• 8.4 Analysis by Sample Type
• 8.5 Analysis by Clinical Application

9. Cardiogenetic Testing Market Segment Analysis (2021-2031)

• 9.1 By Test Type
  • 9.1.1 Diagnostic Testing
  • 9.1.2 Predictive & Presymptomatic Testing
  • 9.1.3 Carrier Testing
  • 9.1.4 Cascade Testing
  • 9.1.5 Prenatal & Preimplantation Genetic Testing
• 9.2 By Technology
  • 9.2.1 Next-Generation Sequencing (NGS)
  • 9.2.2 Whole Exome Sequencing (WES)
  • 9.2.3 Whole Genome Sequencing (WGS)
  • 9.2.4 Targeted Gene Panel Testing
  • 9.2.5 Sanger Sequencing
  • 9.2.6 PCR-Based Testing
  • 9.2.7 Chromosomal Microarray Analysis (CMA)
• 9.3 By Disorder Type
  • 9.3.1 Inherited Cardiomyopathies
    • 9.3.1.1 Hypertrophic Cardiomyopathy (HCM)
    • 9.3.1.2 Dilated Cardiomyopathy (DCM)
    • 9.3.1.3 Arrhythmogenic Cardiomyopathy (ACM/ARVC)
    • 9.3.1.4 Restrictive Cardiomyopathy (RCM)
  • 9.3.2 Inherited Arrhythmia Syndromes
    • 9.3.2.1 Long QT Syndrome
    • 9.3.2.2 Brugada Syndrome
    • 9.3.2.3 Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
    • 9.3.2.4 Short QT Syndrome
  • 9.3.3 Familial Aortopathies & Connective Tissue Disorders
    • 9.3.3.1 Marfan Syndrome
    • 9.3.3.2 Loeys-Dietz Syndrome
    • 9.3.3.3 Vascular Ehlers-Danlos Syndrome
  • 9.3.4 Familial Hypercholesterolemia
  • 9.3.5 Other Inherited Cardiovascular Disorders
• 9.4 By Gene Panel Type
  • 9.4.1 Single-Gene Testing
  • 9.4.2 Multi-Gene Panel Testing
  • 9.4.3 Whole Exome Sequencing
  • 9.4.4 Whole Genome Sequencing
• 9.5 By Sample Type
  • 9.5.1 Blood
  • 9.5.2 Saliva/Buccal Swab
  • 9.5.3 Tissue & Other Specimens
• 9.6 By End User
  • 9.6.1 Hospitals
  • 9.6.2 Specialty Cardiology Clinics
  • 9.6.3 Diagnostic Laboratories
  • 9.6.4 Academic & Research Institutes

10. Cardiogenetic Testing Market Geographical Analysis (2021-2031)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Cardiogenetic Testing Market Country Analysis (2021-2031)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Netherlands
• 11.9 Japan
• 11.10 China
• 11.11 India
• 11.12 South Korea
• 11.13 Australia
• 11.14 Brazil
• 11.15 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
• 13.2 Illumina, Inc.
• 13.3 Eurofins Scientific SE
• 13.4 Quest Diagnostics Incorporated
• 13.5 Laboratory Corporation of America Holdings (Labcorp)
• 13.6 Invitae Corporation
• 13.7 Natera, Inc.
• 13.8 GeneDx Holdings Corp.
• 13.9 Centogene N.V.
• 13.10 Blueprint Genetics Oy
• 13.11 Ambry Genetics Corporation
• 13.12 Fulgent Genetics, Inc.
• 13.13 Exact Sciences Corporation (PreventionGenetics)
• 13.14 3billion Inc.
• 13.15 Myriad Genetics, Inc.

14. Cardiogenetic Testing Market Commercial Forecast Analysis

• 14.1 Multi-Gene Cardiovascular Panel Testing
• 14.2 Whole Exome Sequencing Services
• 14.3 Whole Genome Sequencing Services
• 14.4 Familial Hypercholesterolemia Genetic Testing
• 14.5 Hypertrophic Cardiomyopathy Genetic Testing
• 14.6 Inherited Arrhythmia Syndrome Genetic Testing
• 14.7 Comprehensive Hereditary Cardiovascular Disease Testing Services

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends